This is not the latest version of this item. The latest version can be found here.
Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development
Name
hum.2020.263.pdf
Description
Published version
Size
330.8 KB
Format
Adobe PDF
Checksum (MD5)
e6e23cd4e45f6d75aeb1178eb5e7e3ee
Author(s)
Cannon, Paula
Asokan, Aravind
Czechowicz, Agnieszka
Hammond, Paula
Kohn, Donald B
Lieber, Andre
Malik, Punam
Marks, Peter
Porteus, Matthew
Verhoeyen, Els
Date Issued
2021
Journal
Human Gene Therapy
Publisher
Mary Ann Liebert Inc
Citation
Cannon, Paula, Asokan, Aravind, Czechowicz, Agnieszka, Hammond, Paula, Kohn, Donald B et al. 2021. "Safe and Effective In Vivo Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development." Human Gene Therapy, 32 (1-2).
Version
Final published version
Abstract
On May 11, 2020, the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation (Gates Foundation) held an exploratory expert scientific roundtable to inform an NIH-Gates Foundation collaboration on the development of scalable, sustainable, and accessible HIV and sickle cell disease (SCD) therapies based on in vivo gene editing of hematopoietic stem cells (HSCs). A particular emphasis was on how such therapies could be developed for low-resource settings in sub-Saharan Africa. Paula Cannon, PhD, of the University of Southern California and Hans-Peter Kiem, MD, PhD, of the Fred Hutchinson Cancer Research Center served as roundtable cochairs. Welcoming remarks were provided by the leadership of NIH, NHLBI, and BMGF, who cited the importance of assessing the state of the science and charting a path toward finding safe, effective, and durable gene-based therapies for HIV and SCD. These remarks were followed by three sessions in which participants heard presentations on and discussed the therapeutic potential of modified HSCs, leveraging HSC biology and differentiation, and in vivo HSC targeting approaches. This roundtable serves as the beginning of an ongoing discussion among NIH, the Gates Foundation, research and patient communities, and the public at large. As this collaboration progresses, these communities will be engaged as we collectively navigate the complex scientific and ethical issues surrounding in vivo HSC targeting and editing. Summarized excerpts from each of the presentations are given hereunder, reflecting the individual views and perspectives of each presenter.
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
10.1089/hum.2020.263
